BRAF and melanoma: IMspire150 (NCT02908672) was a randomized, double-blind, placebo-controlled phase 3 clinical trial that assessed vemurafenib and cobimetinib with or without atezolizumab in patients with metastatic BRAF-mutated melanoma.